Trials / Recruiting
RecruitingNCT06517888
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Akouos, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | AAVAnc80-antiVEGF via Akouos Delivery Device | AAVAnc80-antiVEGF is a sterile suspension intended to be administered via intracochlear administration as a single dose using the Akouos Delivery Device |
Timeline
- Start date
- 2025-01-17
- Primary completion
- 2029-08-01
- Completion
- 2029-08-01
- First posted
- 2024-07-24
- Last updated
- 2026-04-06
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06517888. Inclusion in this directory is not an endorsement.